Controlling Rapid Atrial Fibrillation With Dexmedetomidine
Status:
Unknown status
Trial end date:
2020-06-20
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effects of Dexmedetomidine (DEX), on heart rate
control in patients with rapid atrial fibrillation (AF) through a pragmatic, randomized,
double blinded study comparing the addition of Dex or placebo to standard of care (SOC)
treatment.